- Home
- PRME vs JANX Comparison
PRME vs JANX Comparison
Compare PRME & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | JANX |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 790.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRME | JANX |
|---|---|---|
| Price | $3.42 | $15.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $7.56 | ★ $53.60 |
| AVG Volume (30 Days) | ★ 2.1M | 949.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $10,000,000.00 |
| Revenue This Year | $12.41 | N/A |
| Revenue Next Year | $52.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.11 | $12.12 |
| 52 Week High | $6.94 | $35.34 |
Technical Indicators
Market Signals| Indicator | PRME | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 61.72 |
| Support Level | $3.17 | $13.10 |
| Resistance Level | $3.94 | $15.49 |
| Average True Range (ATR) | 0.25 | 0.56 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 47.17 | 83.61 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.